Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

53° Cloudy
- Bishop, CA (93514)
  Today
  
  Cloudy with periods of rain. High 57F. Winds S at 5 to 10 mph. Chance of rain 100%. Locally heavy rainfall possible..
  
  Tonight
  
  Periods of rain. Low 42F. Winds SSW at 5 to 10 mph. Chance of rain 100%. Rainfall near a half an inch.
  
  Updated: November 15, 2025 @ 10:08 am
- Full Forecast

Site search

Home
News
Sports
Obituaries
e-Edition
Special Sections
Classifieds
- Place an ad
Archives

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

232.36 +0.07 (+0.03%)

Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

89 90 Next >

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion ↗

March 12, 2025

The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.

Via Investor's Business Daily

Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever. ↗

March 12, 2025

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

March 11, 2025

Via Benzinga

Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You? ↗

March 11, 2025

Vanguard has some excellent dividend ETFs, but they are right for different investors.

Via The Motley Fool

Topics ETFs

AbbVie Options Trading: A Deep Dive into Market Sentiment ↗

March 07, 2025

Via Benzinga

13 Analysts Have This To Say About AbbVie ↗

March 04, 2025

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

March 04, 2025

Via Benzinga

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years ↗

February 24, 2025

Via Benzinga

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

March 11, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...

Via StockStory

Topics Artificial Intelligence

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas ↗

March 10, 2025

There's a lot going on for investors.

Via The Motley Fool

This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy? ↗

March 10, 2025

Via The Motley Fool

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week ↗

March 10, 2025

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...

Via Stocktwits

3 Stocks Breaking Out Right Now ↗

March 09, 2025

These three stocks are touching new all-time highs.

Via Talk Markets

Topics Stocks / Equities

Is the SPDR S&P 500 ETF Trust the Smartest Investment You Can Make Today? ↗

March 09, 2025

Via The Motley Fool

Topics ETFs Stocks

3 Cheap Stocks to Buy With Your Tax Refund Check ↗

March 07, 2025

Via The Motley Fool

2 Dividend Stocks to Buy for a Lifetime of Passive Income ↗

March 07, 2025

Via The Motley Fool

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

March 04, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.

Via StockStory

Topics Artificial Intelligence

AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race ↗

March 03, 2025

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

Via Benzinga

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. ↗

March 03, 2025

This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1.

Via Investor's Business Daily

These Vanguard ETFs Show Where the Smart Money Is Moving Now ↗

March 03, 2025

Via The Motley Fool

Topics ETFs

4 Sectors That Thrive When Inflation Runs Hot

February 28, 2025

Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value

Via MarketBeat

Topics Economy World Trade

3 Reasons ABBV is Risky and 1 Stock to Buy Instead

February 28, 2025

AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%.

Via StockStory

Topics Stocks

10 Health Care Stocks Whale Activity In Today's Session ↗

February 27, 2025

Via Benzinga

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

February 27, 2025

Via The Motley Fool

2 High-Yield Dividend ETFs to Buy to Generate Passive Income ↗

February 23, 2025

With yields ranging between 3.6% and 7.3%, these dividend ETFs are great bets for generating passive income.

Via The Motley Fool

Topics ETFs

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

February 22, 2025

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

Via MarketBeat

Topics Death

Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗

February 20, 2025

Tariffs could have big impact on earnings in 2025.

Via Talk Markets

Topics Stocks / Equities

2 Magnificent Dividend Growth Stocks to Load Up On Right Now ↗

February 20, 2025

Via The Motley Fool

4 Stocks and 1 Exchange-Traded Fund (ETF) I Can't Stop Buying ↗

February 19, 2025

Five great investments for any portfolio.

Via The Motley Fool

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings

February 18, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know.

Via StockStory

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

89 90 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Local Events
Obituaries
Multimedia
Online Features
Announcements

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

Contact Information

InyoRegister.com
407 W. Line St. #8
Bishop, CA 93514
Phone: 760-873-3535

Advertising

Retail Sales: egalanski@inyoregister.com
Classified Sales: classy@inyoregister.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Bishop, CA (93514)

Today

Tonight

AbbVie (NY:ABBV)

All News about AbbVie

Sections

Services

Contact Information